ArticleQuantitative imaging in medicine and surgery2026
Q.Liver software for the planning of treatment of liver cancer via transarterial radioembolization with yttrium-90 resin microspheres based on single-photon emission computed tomography-computed tomography.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence across oncologic theranostics: evidence for patient stratification, dosimetry, and adaptive radiopharmaceutical therapy.Frontiers in nuclear medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) and liver-dominant metastases remain major causes of cancer mortality, and yttrium-90 transarterial radioembolization (TARE) offers a vital treatment option for unresectable cases. Accurate dosimetry is critical for maximizing tumor control while minimizing lung toxicity, yet conventional planar scintigraphy may overestimate lung shunt and compromise therapeutic efficacy. This study evaluated the value of Q.Liver software in planning yttrium-90 TARE for liver cancer. Methods: A total of 45 patients with liver cancer scheduled for treatment with yttrium-90 resin microspheres TARE were enrolled. Treatment planning was conducted via the partition model with two approaches for each case: the traditional method based on planar scintigraphy and the Q.Liver software based on single-photon emission computed tomography-computed tomography (SPECT/CT) imaging. Differences in liver and lung volume between the two methods were compared. Differences in lung shunt fraction (LSF) were analyzed in 43 patients, and yttrium-90-prescribed activity, liver-absorbed dose (D Results: (I) The liver and lung volumes in the planar and Q.Liver methods were 1,809 and 1,820 mL (P=0.36), respectively, and 3,279 and 2,587 mL (P<0.05), respectively. (II) The LSF in the planar method was higher than that in the Q.Liver method (6.08% Conclusions: SPECT/CT-based Q.Liver software was able to simplify yttrium-90 treatment. Planar scintigraphy overestimated LSF and D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.